Annual report [Section 13 and 15(d), not S-K Item 405]

CONSOLIDATED BALANCE SHEETS

v3.25.1
CONSOLIDATED BALANCE SHEETS - USD ($)
Dec. 31, 2024
Dec. 31, 2023
Current assets:    
Cash $ 88,033 $ 65,222
Accounts receivable, net 0 740
Grant receivable 0 76,266
Prepaid expenses 29,963 44,891
Total current assets 117,996 187,119
Property and equipment, net 18,977 50,943
Right to use assets 199,184 97,278
Other assets:    
Patents, net 7,848 9,027
Deposits, long term 41,936 44,520
Total other assets 49,784 53,547
Total assets 385,941 388,887
Current liabilities:    
Accounts payable and accrued expenses, including related party payables of $1,349,465 and $1,683,453, respectively 5,574,831 4,649,179
Deferred revenue, grant 56,590 0
Lease liability, short term 40,057 122,732
Derivative liability 0 53,460
Notes payable, net of debt discount of $41,452 and $354,730, respectively 1,343,278 606,750
Notes payable, related parties, net of debt discount 1,192,859 999,088
Total current liabilities 8,207,615 6,431,209
Long term liabilities:    
Economic Injury Disaster loan, long term 71,029 72,466
Royalty obligation, net of discount of $4,418,698 and $4,899,354, related parties 4,303,402 3,822,746
Lease liability, long term 159,127 10,945
Deferred revenue, long term 0 4,045
Total liabilities 12,741,173 10,341,411
Deficit:    
Common stock, $0.001 par value; 750,000,000 shares authorized, 13,299,349 and 8,674,029 shares issued and outstanding as of December 31, 2024 and 2023, respectively 13,299 8,674
Common stock subscribed 100,000 100,009
Additional paid in capital 70,953,807 68,149,029
Accumulated deficit (83,209,142) (78,103,018)
Total deficit attributable to BioCorRx, Inc. (12,120,420) (9,823,690)
Non-controlling interest (234,812) (128,834)
Total deficit (12,355,232) (9,952,524)
Total liabilities and deficit 385,941 388,887
Convertible Series A Preferred Stock [Member]    
Deficit:    
Preferred Stock Value 16,000 16,000
Convertible Series B Preferred Stock [Member]    
Deficit:    
Preferred Stock Value $ 5,616 $ 5,616